Veltre will develop the company’s media and digital strategy.
Bill Veltre is joining Deerfield Agency as executive vice president and head of media. The marketing firm announced the new hire in a press release.1 In his new role, Veltre will oversee paid media services and will work to further develop the company’s media and digital strategy.
In a press release, Veltre said, “I am thrilled to join the Deerfield team and play a key role in driving the agency's continued success. Critical to pharmaceutical marketing today is how to effectively engage with HCPs and patients and how we leverage insights to improve the effectiveness of marketing efforts. Deerfield has built a true marketing engine powered by omnichannel approaches, data and analytics, and creative strategy. I'm looking forward to partnering with my new colleagues to continue to refine our approaches and help our clients deliver on the promise of their products."
In the same release, Deerfield Agency’s managing partner Frank Burrell said, “Bill's appointment signifies an exciting milestone for Deerfield Agency as our media service offerings grow and we continue to enhance our media insights and reporting capabilities. Recognized as a dedicated media-enthusiast and provocative thought leader, Bill will explore new opportunities in digital marketing and reporting, helping our clients drive meaningful engagement with patients and health care professionals."
According to the press release, Veltre isn’t just bringing a wealth of experience in media. A major factor in his hiring is his experience dealing with analytics. Deerfield Agency is taking an analytical approach to its media and digital strategy, and Veltre is expected is to help move this directive forward.
Deerfield Agency is a full-service agency that provides marketing, advertising, and communications services. It describes itself as a company that crafts stories and focuses on the connections related to human health. It provides omnichannel marketing, creative, digital, media, print, public relations, and analytic services.
Veltre is the latest new hire at Deerfield Agency.
In February, the agency announced that it brought Eric Steckelman onboard as lead of business development and marketing.2 Steckelman has experience in growth strategy, which played a key role in his hiring.
In a press release, Steckelman said, “"I am really excited to partner with the entire Deerfield team and continue to build on the agency's success to date. Deerfield has grown significantly, a testament to the team's commitment and ability to identify and solve marketing challenges. With a real focus on insights, story and measurement, and broad capabilities across healthcare marketing, advertising and communications, we are well positioned for continued growth and impact."
In the same press release, Burrell said, “"Eric's appointment marks an exciting chapter for Deerfield Agency as we continue to expand our capabilities and drive innovation as an Agency of Brand® in the healthcare and life sciences industries. With a proven track record in new business growth and development, along with expertise in assessing market trends and opportunities, we are confident that Eric will play a key role in deepening and expanding client relationships and broadening visibility for the agency."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.